✦ LIBER ✦

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient

✍ Scribed by A. Makis; N. Chaliasos; E. Hatzimichael; K. Bourantas

Publisher: Springer
Year: 2001
Tongue: English
Weight: 22 KB
Volume: 80
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s002770100317

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Transfusion-induced malaria in a splenec

Transfusion-induced malaria in a splenectomized β-thalassemia major patient and review of blood donor screening methods

✍ Suresh K. Joishy; Cynthia G. Lopez 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 476 KB

## Abstract Transfusion‐induced malaria may be a serious threat to the life of a group of special patients: those who require many transfusions, those who have been treated with immunosuppressants, and those who have undergone splenectomy. We describe transfusion‐induced malaria in a β‐thalassemia

Correction of anemia by recombinant huma

Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis-dependent chronic renal failure

✍ Junko H. Ohyashiki; Hiromi Fujieda; Kazuma Ohyashiki; Keisuke Toyama 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

Controlled multicentre study of the infl

Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

✍ WW ten Bokkel Huinink; CAM de Swart; DW van Toorn; G Morack; WPM Breed; HFP Hill 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 734 KB

Ratio of baseline erythropoietin (EPO) l

Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients

✍ Navapun Charuruks; Narin Voravud; Wacharee Limpanasithikul 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract Purpose: Recently, recombinant human erythropoietin (rhEPO) was introduced for the management of anemia in malignancy. To identify an indicator for a favourable response to rhEPO, 28 anaemic cancer patients undergoing chemotherapy and treated with rhEPO were evaluated. Methods: Patients